A Safety and Effectiveness Pilot Study of PRF-108 and PRF-110 in Healthy Volunteers
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This is a clinical study testing PRF-108 and PRF-110 (a new extended release 4% gel
formulations of ropivacaine) in an experimentally induced pain model in healthy volunteers.
PRF-108 and PRF-110 are designed to deliver slow release of ropivacaine over 72 hours.